MHC proteins are an essential component of the adaptive immune system, due to their role in presenting self and foreign processed peptides for inspection by T cells^[@R1]^. Human MHC genes - also referred to as HLA (Human Leukocyte Antigen) genes - are extremely polymorphic, and variants of these genes have been associated with many traits, including most autoimmune diseases^[@R2],[@R3]^. It has been suggested that in some cases the increased disease risk conferred by particular MHC alleles is due to differences in the peptides they present, or to differences in the intrinsic stability of the MHC variants^[@R4]^. However, beyond their importance in shaping the sequence repertoire of antigenic peptides presented, in most cases we still have limited understanding of the functional implications of different MHC alleles and their interplay with TCR diversity^[@R3],[@R4]^.

One possible functional effect of MHC genotypes could be to impact the usage of paralogous genes that encode the TCR repertoire. Each individual has a highly diverse TCR repertoire that is able to recognize and respond to a huge variety of foreign peptides when they are presented on MHC proteins. Each TCR is a heterodimer, usually comprised of α (TRA) and β (TRB) chains (1--5% of T cells instead carry γ (TRG) and δ (TRD) chains^[@R5]^). Each T cell clone expresses a unique pair of TCR chains resulting from somatic V(D)J recombination of one of each of the paralogous variable (V), joining (J) and, in β and δ chains, diversity (D) genes. During this recombination, the joints are partially digested and nucleotides are randomly added to form the highly variable and non-germline-encoded Complementarity Determining Region (CDR) 3 loop that recognizes presented peptides^[@R6]^. Additional contacts with the MHC are formed by the CDR1 and CDR2 loops of the T cell receptor, which are encoded by the V-genes^[@R6]--[@R10]^. T cells subsequently undergo both positive and negative selection in the thymus to ensure specificity for foreign, but not for self, peptides^[@R11]^.

The TCR repertoire is reshaped in response to infection^[@R8],[@R12]^ and varies between individuals^[@R13]^. However, little is known about the extent to which the usage of different V-genes in the TCR repertoire is shaped by host genetics, apart from limited observations of increased repertoire similarity among close relatives^[@R14],[@R15]^, and a report that usage of Vα genes in response to an EBV epitope depends on HLA-B genotype^[@R16]^. Moreover, while it is intuitive that MHC genotype might affect the TCR repertoire, the precise nature of the MHC-TCR interaction remains controversial. In contrast to B-cell-secreted antibodies (which are also generated by V(D)J recombination), TCRs interact specifically with MHC-peptide complexes. Yet despite numerous structural, *in vitro,* and murine *in vivo* studies, there is still active debate about whether the germline-encoded TCR-MHC contacts help to promote this specificity^[@R10],[@R17]--[@R23]^ or are merely bystanders^[@R24]--[@R26],[@R23]^. Recent studies have reported conflicting conclusions on this point^[@R26],[@R27]^. If germline-encoded contacts influence TCR-MHC interaction, then we might expect different TCR V-genes to differ in their compatibilities with different MHC alleles. Such differences might bias V-gene usage in the post-thymic repertoire, since both thymic selection and clonal expansion of T cells are dependent on TCR-MHC interactions^[@R21]^.

Here, we address the question of how the host genotype influences the make-up of the TCR repertoire using expression quantitative trait loci (eQTL) analysis^[@R28]^ of a large human cohort^[@R29]^ for which both RNA sequencing of peripheral blood and genotyping data are available ([Fig. 1](#F1){ref-type="fig"}). We took an undirected approach of testing, genome-wide, for *trans* associations between genetic variation and expression of TCR V-genes. (We will also use the term 'bias' to refer to genotype-dependent shifts in V-gene usage). Our results suggest that MHC genotypes play an important role in determining the V-gene usage profiles of each individual's TCR repertoire.

Results {#S1}
=======

Expression of TCR V-genes is associated with MHC variation {#S2}
----------------------------------------------------------

We analyzed RNA-sequencing (RNA-seq) data collected from the peripheral blood of 922 individuals^[@R29]^ of European ancestry. To estimate the relative expression of each V-gene, we counted the number of reads that mapped uniquely to each V-gene while controlling for the total expression of each TCR chain and other relevant covariates ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}; [Fig. 1](#F1){ref-type="fig"}, [Supplementary Figs 1 and 2](#SD1){ref-type="supplementary-material"}; see **Methods**). After removing genes and individuals with low numbers of mapped reads, we obtained expression measurements for 44 Vα, 40 Vβ, 11 Vγ and 3 Vδ genes in each of 895 individuals ([Supplementary Tables 2 and 3](#SD1){ref-type="supplementary-material"}; [Supplementary Figs. 3--5](#SD1){ref-type="supplementary-material"}). Since ordinarily only one functional TCR is expressed in each T cell, the estimated expression levels will be determined by the fraction of T cells expressing each TCR, as well as the expression level of the TCR in each cell. As a control, we applied a similar pipeline to analyze the V-genes from B cell-secreted antibodies (immunoglobulin; Ig), which are not expected to interact with MHC.

To test for associations between genotype and the expression of TCR V-genes, we used genome-wide genotype measurements in the same individuals^[@R29]^ ([Fig. 1](#F1){ref-type="fig"}). We initially tested for short-range eQTLs, i.e., within 1Mb of each V-gene. We excluded from this analysis a small number of genes in which read mappability varies across haplotypes ([Supplementary Fig. 6](#SD1){ref-type="supplementary-material"}; see **Methods**). As expected, we found many short-range eQTLs - for 78% of TCR V-genes and 46% of Ig V-genes at 5% False Discovery Rate (FDR) ([Supplementary Fig. 7a](#SD1){ref-type="supplementary-material"}; [Supplementary Table 4](#SD1){ref-type="supplementary-material"}) - presumably reflecting *cis*-acting effects on gene regulation.

We next tested genome-wide for long-range eQTLs. Notably, we found multiple highly significant associations between the MHC locus and expression of TCR V-genes. 47.7% and 22.5% of the Vα and Vβ genes, respectively, were associated at a stringent threshold of p\<5×10^−8^, which accounts for genome-wide significance testing ([Figs. 2a and 2b](#F2){ref-type="fig"}, [Supplementary Fig. 8](#SD1){ref-type="supplementary-material"}; [Supplementary Table S5](#SD1){ref-type="supplementary-material"}). Restricting the analysis to the extended MHC locus reduces the multiple testing burden so that 66% and 35% of the Vα and Vβ genes, respectively, were significantly associated with variation in the MHC locus at a 5% FDR ([Supplementary Fig. 7b](#SD1){ref-type="supplementary-material"}; [Supplementary Table 4](#SD1){ref-type="supplementary-material"}; see **Methods**). The MHC locus stands out, as we observed just one other genome-wide significant *trans* association with any TCR V-gene (*TRVB24-1*, associated with variation near ZNF443) ([Figs. 2a, 2b](#F2){ref-type="fig"}, and [Supplementary Fig. 9](#SD1){ref-type="supplementary-material"}). Interestingly, despite the lack of MHC restriction of γδ-TCRs^[@R30]^, the few significant associations with expression of Vδ-genes also mapped to the MHC locus ([Figs. 2c and 2d](#F2){ref-type="fig"}). We speculate that these associations might be caused by the small population of δβ T cells that recognize MHC-presented peptides^[@R30]^. Importantly, there were no genome-wide significant associations between MHC and the Ig V-genes, which encode antibodies ([Figs. 2e--2g](#F2){ref-type="fig"}, [Supplementary Figs. 7b and 8](#SD1){ref-type="supplementary-material"}), and just one association between MHC variants and any other gene ([Fig. 2h](#F2){ref-type="fig"}), highlighting the specific relationship between MHC and TCR.

Classical MHC genes drive most MHC locus-TCR associations {#S3}
---------------------------------------------------------

To localize functional elements in the MHC locus that associate with Vα or Vβ expression, we used the genotyped SNPs to impute genotype estimates for all known MHC variants^[@R31]^ ([Fig. 1](#F1){ref-type="fig"}). We then performed forward stepwise regression to identify independent associations with any SNPs within the MHC locus or with amino acid polymorphisms in classical MHC genes. We iteratively added polymorphic positions to a predictive model of each gene's expression until no additional position significantly improved the model fit (F-test, p-value threshold=0.05 under Bonferroni correction; [Fig. 3a](#F3){ref-type="fig"}, [Supplementary Fig. 10](#SD1){ref-type="supplementary-material"}; [Supplementary Table 6](#SD1){ref-type="supplementary-material"}, see **Methods**).

Using this conservative threshold, we identified 66 independent MHC-TCR associations for 28 TCR Vα and 15 Vβ genes. These associations explained from 2.2% to 37% of the expression variation of each V-gene ([Supplementary Fig. 11](#SD1){ref-type="supplementary-material"} and [Supplementary Table 7](#SD1){ref-type="supplementary-material"}). It is often difficult to precisely locate causal sites in QTL mapping due to linkage disequilibrium (LD - i.e., the property that genotypes at linked sites tend to be correlated). Nonetheless, despite the fact that LD tends to spread association signals, we observed strong enrichment of signals within transcribed regions of classical MHC genes, especially in *HLA-DRB1*. 42 of 66 associations are in MHC genes - of these 37 are in class II and 25 are in the class II gene *HLA-DRB1* alone (these are 3.5--, 7.5-- and 15.8--fold enrichments respectively, relative to all variants). In addition, many of the remaining 24 associations outside genes are near classical MHC proteins, and may thus be in LD with causal variants in genes. The larger number of associations with variation in MHC class II proteins than in MHC class I proteins may be biologically meaningful, but it might also reflect greater power in our data set to detect class II interactions due to the higher abundance of CD4 than CD8 T cells in peripheral blood^[@R32]^.

To test the robustness of our results, we conducted two further analyses. First, we tested for independent associations using classical MHC 4-digit haplotypes instead of nucleotide and amino acid variation. This analysis yielded qualitatively similar results: 75 of 92 associations were with MHC class II haplotypes; of these, 32 were with *HLA-DRB1* haplotypes (these are 1.6- and 2.4-fold enrichments respectively, relative to all classical MHC haplotypes; ([Supplementary Figs. 12--13](#SD1){ref-type="supplementary-material"}, and [Supplementary Table 8](#SD1){ref-type="supplementary-material"}). *HLA-DRB1\*03:01* was associated with the largest number of different V-genes (12 genes). Second, we performed a joint multi-phenotype regression analysis. This analysis also indicated that MHC class II genes and especially *HLA-DRB1* contribute the most signals ([Supplementary Figs. 14--16](#SD1){ref-type="supplementary-material"}, **Methods**).

To assess the specific contribution of coding variants to these associations, we used a variance components method designed for genomic data, GCTA^[@R33]^, to estimate the fraction of the expression variation of TCR V-genes that can be explained by coding variants in classical MHC genes. We fit a model with genetic components representing the amino acid variation in each MHC gene, and a component for variants in the MHC locus outside the transcribed regions of classical MHC genes ([Figs. 3b and 3c](#F3){ref-type="fig"}, and [Supplementary Figs. 17--22](#SD1){ref-type="supplementary-material"}). We found that amino acid variants in MHC genes explain a significant fraction of expression variation for 33 out of 44 TCR Vα genes and 16 of 40 Vβ genes and 92% and 88%, respectively, of the total variance explained ([Figs. 3b and 3c](#F3){ref-type="fig"}, [Supplementary Fig. 21](#SD1){ref-type="supplementary-material"}; 5% FDR, see **Methods**). As a negative control, only one Ig V-gene out of 149 was significant at a 5% FDR. For significant TCR V-genes, the fraction of variance explained ranges from 5--75% (additional variance may be due to environmental or random factors as well as measurement noise - especially for genes expressed at low levels; [Supplementary Fig. 22](#SD1){ref-type="supplementary-material"}). Thus, in summary, we conclude that the vast majority of the TCR variation explained by the MHC locus is due to amino acid variation in MHC proteins, with major contributions of MHC class II β chains and especially *HLA-DRB1*.

MHC residues that bias TCR expression contact the TCR {#S4}
-----------------------------------------------------

Our next goal was to infer which amino acid positions are most likely responsible for expression biases of the TCR V-genes (see **Methods**). Since many of the positions are in strong LD, it is often unclear which position is causal for a particular association. To quantify the uncertainty, we implemented a Bayesian Markov chain Monte Carlo (MCMC) approach that sampled over the joint distribution of potential causal positions that are consistent with the association data for each V-gene. Compared to frequentist approaches such as variable selection methods, which generally make firm choices about which sites to include, Bayesian models are generally better at quantifying and reflecting the uncertainty due to LD^[@R34]--[@R37]^. Our model started with a low, uniform prior probability that any given amino acid position would be causal, and incorporated the intuition that if a particular position is causal for one variant then it may be more likely causal for others as well (separately for Vα and Vβ genes). The model outputs a posterior probability that any given amino acid position is causally associated with expression of a particular V-gene or with any V-gene, while accounting for correlations across sites due to LD.

The results revealed several MHC amino acid positions with high posterior probabilities of influencing expression of TCR Vα-genes ([Fig. 4](#F4){ref-type="fig"} and [Supplementary Table 9](#SD1){ref-type="supplementary-material"}), though for some associations the posterior is shared across multiple potential causal positions in strong LD ([Supplementary Fig. 23](#SD1){ref-type="supplementary-material"}). Interestingly, three of the top 15 amino acid positions influencing expression of TCR Vα-genes (*HLA-DRB1* 71 and 86, *HLA-DQB* 57) are strongly associated with several autoimmune diseases. Alleles of these three amino acids are strongly correlated with expression biases of TCR Vα-genes ([Supplementary Fig. 24](#SD1){ref-type="supplementary-material"}). For example, *HLA-DRB1* 71, the third-ranked amino acid position, is strongly associated with seropositive rheumatoid arthritis, type 1 diabetes and multiple sclerosis^[@R38]--[@R40]^. Different variants of the amino acid at this position are correlated with increased expression of different V-genes. It is possible that TCR V-gene expression biases, previously shown to affect the outcome of autoimmunity and infection^[@R41],[@R42]^, are related to some MHC associations with autoimmune and infectious disease risk. Consistent with the analysis above, we found fewer positions that likely influence expression of TCR Vβ-genes ([Supplementary Fig. 25](#SD1){ref-type="supplementary-material"} and [Supplementary Table 10](#SD1){ref-type="supplementary-material"}).

If the detected associations result from MHC residues influencing the TCR-peptide-MHC interaction, then the relevant residues should cluster near the contact interface involved in TCR interaction with MHC or the presented peptide (influencing the TCR indirectly). *A priori*, MHC residues that affect TCR germline interactions could be direct pairwise structural contacts, or could cause indirect effects relayed through subtle conformational changes of the MHC or peptide from within the MHC groove, as seen for alloreactive MHC in graft rejection^[@R43]^.

To test whether the associated residues tend to be at or near the TCR-peptide-MHC interface, we first superimposed our genetic mapping results for DRB1 residues onto protein structures of class II MHC-TCR interactions ([Figs. 5a and 5b](#F5){ref-type="fig"}). Remarkably, the residues with high posterior probability of influencing V-gene usage tend to be either physically near, or in direct contact with the TCR in structures that contain DRB1 ([Fig. 5d](#F5){ref-type="fig"}). We next aligned structures of TCRs bound to human class II MHCs and identified all contacts between the DRB, DQB, or DPB chains and any of the TCRα chains or the presented peptides ([Fig. 5e](#F5){ref-type="fig"}, and [Supplementary Figs. 26--27](#SD1){ref-type="supplementary-material"}; see **Methods** for details).

Despite the large diversity in TCRα-MHCβ interaction chemistries, a small subset of MHC residues contact TCRα in a large fraction of the structures, in agreement with similar analyses of TCR-MHC class I complexes^[@R25],[@R44]^. For example, residue 77, predicted by our model to influence TCR Vα expression (posterior probability of 0.71), shows diverse but consistent contact with germline TCR residues in all analyzed TCR-class-II MHC complexes ([Fig. 5c](#F5){ref-type="fig"} and [Supplementary Table 11](#SD1){ref-type="supplementary-material"}). To quantitatively test whether MHC amino acid residues near the TCR interaction surface tend to be associated with TCR V-gene expression, we correlated our model posterior probabilities with the mean distance between each MHC residue centroid and the closest TCR ([Supplementary Fig. 28](#SD1){ref-type="supplementary-material"}) or peptide ([Supplementary Fig. 29](#SD1){ref-type="supplementary-material"}) residue centroid in all analyzed complexes. Although inter-residue proximity does not strictly correlate with energetic importance in protein-protein interactions, we found the association probabilities and TCR distances to be significantly correlated ([Supplementary Fig. 30a](#SD1){ref-type="supplementary-material"}; Pearson R= −0.28, p-value=0.022; Spearman R=−0.35, p-value=0.0044). This correlation would be higher if not for one outlier, residue 185, which may either be a false prediction or may indirectly affect the structural integrity of the MHC protein^[@R45]^. The results were similar when distances between amino acid Cα atoms are used instead of distances between centroids ([Supplementary Fig. 30b](#SD1){ref-type="supplementary-material"}). Hence, our structural analysis indicates that several of the residues in close proximity to the TCR or peptide affect expression of TCR V-genes.

Discussion {#S5}
==========

Our results show that MHC genotype plays a key role in shaping the TCR repertoire in a broad population sample, even in the absence of a shared immune challenge. We see an excess of signals in MHC Class II loci, and within *HLA-DRB1* in particular; however it is unclear at this time whether this reflects a greater role for Class II genes in shaping the TCR repertoire, or simply differences in power due to the greater abundance of CD4 T cells in whole blood^[@R32]^. Many of the observed associations are linked to MHC residues, implying a direct role for protein-protein interactions in mediating these effects. We suggest that germline-encoded TCR-MHC compatibilities may bias thymic selection of some V-genes in favor of others, in an MHC-dependent manner.

Further, we were able to fine map some of these signals to specific amino acids that lie at the TCR-pMHC contact interface. Overall we find evidence for the intuitive result that positions near the interaction surface have higher probability of influencing expression of V-genes. That said, not all of the most-associated MHC positions are in direct physical contact with the TCR. More distant associations - e.g., at residue 185 - may reflect LD with other more proximal sites, or may be responsible for longer-range effects within the protein complex. It is known that amino acids distal to contact interfaces do sometimes have important effects on interaction energetics, even when they are not in direct contact^[@R45]^. In particular, this has been shown previously for alloreactive MHC in graft rejection^[@R43]^. Nonetheless, our Bayesian approach does highlight several amino acid residues positioned in the TCR-pMHC contact interface as being important for biasing V-gene usage. To the best of our knowledge, these are the first examples of *trans* associations mediated by protein-protein interactions.

Our observations also have implications for a long-standing debate about the basis of TCR specificity for MHC molecules, and the molecular forces responsible for MHC restriction. In 1971 Niels Jerne postulated that germline TCR and MHC genes co-evolved to be predisposed towards interacting^[@R46]^ - a phenomenon also referred to as 'germline bias'. Our observation that MHC genotype has a direct association with TCR V-gene usage in the broader population implies that germline-encoded TCR-MHC contacts influence their interaction specificity. This orthogonal genetic evidence is in agreement with a variety of structural and functional data supporting a model of intrinsic specificity between TCR and MHC proteins. Other examples of supportive data include structural studies of numerous TCR-pMHC complexes that show persistent germline contacts between V-regions and MHC molecules^[@R20],[@R47]--[@R49]^ and compatible residues between TCR loops and *HLA-A\*02:01*^[@R50]^. Some of these contacts are necessary for functional recognition of MHC molecules and, when mutated, can lead to drastically altered outcomes of thymic selection^[@R20],[@R21]^. Germline-derived Vα elements have been shown to influence MHC class I versus II selection^[@R51]^. Moreover, T cells have recently been shown to recognize MHC molecules independent of the MHC allele and peptide^[@R27]^, supplying functional evidence that the TCR has intrinsic specificity for the MHC via germline-encoded V-genes. Other studies argue against the intrinsic specificity model. For example, it has been reported that specific MHC residues are not essential for TCR recognition^[@R25]^ and there are no known constraints on the CDR sequences^[@R24]^; TCRs in mice that lack MHC I & II, CD4 and CD8 are activated by a non-MHC ligand^[@R23]^; and recently two TCR-pMHC structures composed of the same V-genes showed reversed polarity for MHC binding^[@R26]^. Our observations that TCR-MHC compatibilities exist within a large cohort of individuals likely reflect how most (though not necessarily all) TCR-MHC interactions occur. This leads us to view the studies that are discordant with the co-evolution model as representing *bona fide* deviations from a 'canonical' continuum of TCR-MHC recognition modes. Some level of 'non-canonical' recognition may be expected, considering the enormous repertoire of TCR sequences possible through recombination. In summary, our genetic results are in agreement with some degree of 'hard-wired' TCR-MHC recognition and are supportive of the Jerne Hypothesis.

One key limitation of our approach is that it is based on RNA sequencing of peripheral whole blood. Therefore, our measurements reflect average V-gene usage across different sub-populations of T cells, most notably, aggregating across the CD4 and CD8 T cell subsets. Previous work has identified several variants in the MHC region that are associated with individual-level variation in CD4:CD8 ratios^[@R52]^; moreover, V gene usage differs between CD4 and CD8 cells^[@R53]^. Therefore, one concern is whether the CD4:CD8 variants might drive the signals reported here. However, we find that those SNPs are only modestly associated with our signals ([Supplementary Figs. 31a and 31b](#SD1){ref-type="supplementary-material"}) and are not selected by our conditional analyses ([Fig. 3a](#F3){ref-type="fig"}, and [Supplementary Figs. 12 and 15](#SD1){ref-type="supplementary-material"}). Controlling for those SNPs results in similar, highly significant associations with expression of V-genes ([Supplementary Figs. 31c and 31d](#SD1){ref-type="supplementary-material"}). While we cannot rule out some effect on the fine mapping, especially in the *HLA-B* gene, which reportedly harbors the strongest signal for CD4:CD8 ratio, the localization of the high posteriors to the TCR-pMHC interface suggests that the effect is not very strong. Additionally, some measurement noise may also result from the expansion of particular T cell clones on an individual-specific basis. These, and other, sources of variation are implicitly modeled by our Bayesian fine mapping approach, however, future studies with longer-read sequencing of sorted cell populations may be able to improve mapping resolution. A final concern is the possibility that we may not be able to identify causal residues that are poorly imputed. Most residues in our data have high imputation quality, and we find no correlation between imputation quality and posterior probability ([Supplementary Fig. 32](#SD1){ref-type="supplementary-material"}), however it remains possible that we may have overlooked poorly imputed causal sites.

In summary, we have found that usage of TCR Vα and Vβ-genes is associated with the genotype of MHC proteins. Our structural analysis suggests that these associations result from differences in the specificity of different TCR V-genes to different MHC variants. Our results provide a compelling example of strong *trans* associations that are mediated by protein-protein interaction between a receptor and its ligand, and shed light on the basis of TCR-MHC recognition.

Online Materials and Methods {#S7}
============================

Genotype and TCR V-gene expression data {#S8}
---------------------------------------

We analyzed whole blood RNA sequencing and genotyping data from 922 individuals from the Depression Genes and Networks Project reported by Battle et al.^[@R29]^ (National Institute of Mental Health Grant 5RC2MH089916). Measured SNPs were filtered as described previously, resulting in genotype data at 649,863 SNPs^[@R29]^. The expression of each V-gene relative to the total chain expression was estimated from peripheral blood RNA-sequencing (\~70M 51bp reads per individual). Sequencing reads were mapped as in Battle *et al.* (using Bowtie2^[@R54]^ with Tophat^[@R55]^ default parameters) and the number of unique reads that mapped to each V/J/C-TCR/Ig gene was counted using a modified version of HTSeq^[@R56]^ which allow reads to map to a sequence of more than one V/D/J/C-gene (see [Supplementary Fig. 1](#SD1){ref-type="supplementary-material"} for the average number of reads mapped in an individual to each V-gene). Individuals and genes with low read-counts were removed: specifically, we removed from our analysis individuals with \< 80,000 reads mapping uniquely to TCR/Ig V/D/J/C genes (31% of the median). For analysis, we required that each V-gene have on average \>1 read per individual, at most 100 samples with zero reads, and at least 1% of the individuals with at least 20 reads. Next, the read counts were log transformed (0.1 pseudo reads were added to avoid zeroes); and regressed on known technical and biological confounding factors as in Battle *et al*.^[@R29]^ and on the log total number of reads mapped to each TCR or Ig chain (including reads that mapped to J and C genes; see [Supplementary Table 1](#SD1){ref-type="supplementary-material"}, and [Supplementary Fig. 3](#SD1){ref-type="supplementary-material"}). The median coefficient of variation (CV) of each V-gene was 6% ([Supplementary Fig. 3](#SD1){ref-type="supplementary-material"}). Finally, to avoid the effect of outliers, the residuals were quantile-normalized to a normal distribution (though in practice this made little difference to the detected associations). Similar methodology was applied to Ig V-genes. The final dataset contains measurements of 44 TCR Vα, 40 TCR Vβ, 11 TCR Vγ, 3 TCR Vδ, 31 Ig Vκ, 38 Ig Vλ and 41 Ig VH genes in 895 individuals.

Since read mappability may vary by genotype, we analyzed the mappability of 25-mers from the reference and imputed alternative haplotypes ([Supplementary Fig. 6](#SD1){ref-type="supplementary-material"}). We found that in 9 V-genes \>0% and up to 10% of 25-mers have better mappability to the reference sequence than to alternative haplotypes. We thus excluded all of these genes from the short-range (*cis*) association analysis (thus dropping 6, 1 and 3 TCR Vα, Vβ and Vγ-genes, respectively). We note that mapping differences may increase measurement noise and reduce power for detecting long range (*trans*) associations, but should not create false positives, and therefore these genes were not removed from that analysis. Moreover, we avoid comparing expression of different V-genes, since it is difficult to estimate the mappable lengths of the V-genes due to possible differences between the partial digestion of V-genes and J-gene pairing during V(D)J recombination.

eQTL detection {#S9}
--------------

Associations between genotypes and TCR V-gene-normalized expression values were tested using Pearson correlations. Similarly, in testing for *trans* associations between MHC and other genes, we used Pearson correlations to test all genes at least 1Mb away from the MHC locus against all variants genotyped in the extended MHC locus. The extended MHC locus is defined as the region from the *SLC17A2* gene at the telomeric end to the DAXX gene at the centromeric end of chromosome 6 (hg19 coordinates 25,912,984--33,290,793)^[@R57]^. For genome-wide *trans-*QTL mapping we used a significance threshold of p\<5×10^−8^, which accounts for genome-wide significance testing.

Identification of V-genes that are significantly associated with genotypes in *cis* or in the MHC locus {#S10}
-------------------------------------------------------------------------------------------------------

The empirical significance of the association between the expression of each V-gene and short-range (*cis*) or MHC locus genotype was evaluated by comparing the p-value of the most significantly associated SNP to the most significant p-values in each of 10,000 random permutations of expression values across individuals. 5% FDR was then used to control for the testing of multiple V-genes ([Supplementary Fig. 7](#SD1){ref-type="supplementary-material"}). The SNPs used for the *cis*-analysis were imputed using SHAPEIT^[@R58]^ (for pre-phasing) and IMPUTE2^[@R59]^. The 1000 Genomes Phase 1^[@R60]^ panel was used for imputation with a EUR MAF \> 0.01 filter and genotype likelihood \> 0.9. In testing for *trans* associations with MHC genotypes, we used genotyped SNPs within the extended MHC locus^[@R57]^.

Imputation of MHC locus genotype {#S11}
--------------------------------

SNP2HLA^[@R31]^ was used to impute the MHC locus genotypes, using a reference panel of 5,225 individuals of European descent collected by the Type 1 Diabetes Genetics Consortium^[@R31]^. The software imputes 2 and 4-digit classical alleles for *HLA-A*, *HLA-C*, *HLA-B*, *HLA-DRB1*, *HLA-DQA1*, *HLA-DQB1*, *HLA-DPA1* and *HLA-DPB1*, and their corresponding amino acid (AA) polymorphisms and single-nucleotide polymorphisms (SNPs) ([Fig. 1](#F1){ref-type="fig"}, bottom part). SNPs and polymorphic amino acids with maximum allele frequency \> 97.5 and alleles with frequency lower than 0.5% were removed. The imputation quality (Beagle R^2^ with predicted true genotypes) is larger than 0.95 and 0.99 for 97% and 80% of the imputed amino acids, respectively (excluding alleles with MAF\<2.5%). There is no significant correlation between the imputation quality of amino acid residues, and the posterior probability that they influence expression of TCR V-genes ([Supplementary Fig. 32](#SD1){ref-type="supplementary-material"}).

Conditional analysis of associations between expression of TCR Vα and Vβ-genes and genetic variation in the MHC locus {#S12}
---------------------------------------------------------------------------------------------------------------------

The imputed genotype of each variable amino acid position or nucleotide position was encoded by the allelic dosage variables while omitting the most common allele (a similar encoding was used by Raychaudhuri *et al.*^[@R38]^). The conditional analysis was performed separately for each V-gene using forward stepwise linear regression. In each step of the regression, and for every amino acid residue or nucleotide position, we considered an expanded model that included the allelic dosage variables for that position. The significance was tested using F-tests. If the most significant position had a p-value \< 0.05/*n*, where *n* was the number of tested positions, then this position was added to the model as a covariate. Regression stopped when the p-value of the most significant position was greater than 0.05/*n* (this threshold was p\~10^−5^). We performed two additional variants of this type of analysis. First, instead of testing for associations with nucleotide or amino acids positions in the MHC locus, we tested for associations with classical MHC gene 4-digit haplotypes. Second, instead of testing for associations of MHC genetic variability (at the position or 4-digit haplotype level) with expression of each V-gene separately, we tested for associations with joint expression of all V-genes from a single chain. Since each gene expression was quantile normalized to a normal distribution, using the joint expression of V-genes gives equal weight to explaining the expression of each gene in the chain.

Estimating the fraction of expression variation for each TCR V-gene that is explained by genetic variation in the MHC proteins {#S13}
------------------------------------------------------------------------------------------------------------------------------

We used the Genomewide Complex Trait Analysis tool (GCTA) developed by Yang et al.^[@R33]^. We fit a model with a component for each variable classical MHC protein (*HLA-A*, *HLA-B*, *HLA-C*, *HLA-DRB1*, *HLA-DQA1*, *HLA-DQB1*, *HLA-DPA1*, *HLA-DPB1*) representing the variability at the amino acid level and a component for all SNPs in the MHC locus outside the transcribed regions of the classical MHC genes. Amino acid level variation is used in place of genotype because the annotation of transcribed SNPs in the MHC genes is often ambiguous and allele-dependent. To adapt GCTA to multi-allelic positions, we calculated the genetic relationship between individuals in a multi-allelic position by averaging the relationship over dosage variables of all possible allele. To estimate the significance of the total variation explained by the MHC protein components, we ran GCTA on 100 permutations of the expression data for each TCR V-gene. The fraction of explained variation of these permuted expression vectors follows a truncated normal distribution^[@R61]^. We estimated the variance of this distribution and used it to compute a p-value for the fraction of variation of the expression of each TCR V-gene that is explained by genetic variation in MHC proteins. We corrected for multiple hypothesis testing using 5% FDR^[@R62]^.

Inferring which MHC protein amino acid residues are associated with expression biases of TCR V-genes {#S14}
----------------------------------------------------------------------------------------------------

Identifying which amino acid residues drive the association of the MHC proteins with the expression of TCR V-genes is challenging due to the linkage disequilibrium (LD) between nearby variants. To test the association of each residue while accounting for the genotype of other residues, we used a Bayesian variable selection approach with a spike and slab prior^[@R63],[@R64]^. The Bayesian modeling framework has a number of practical advantages for this problem: in particular, it allows us to appropriately account for the joint uncertainty when there are multiple causal positions and extensive LD. We used priors that reflect our expectation that most residues do *not* directly influence expression, and that a residue that influences expression of one V-gene is more likely to be relevant for expression of other V-genes. The priors were set such that the model required strong evidence to return high posterior probabilities of association.

Specifically, we modeled the expression of each Vα or Vβ gene as a linear combination of the imputed alleles of amino acid residues of classical MHC genes. Each residue's allelic dosage variable can either be included in the model or excluded (coefficient=0) from the model *of* expression of each V-gene. We sampled the space of possible models to estimate the posterior probability that each residue has at least one of its allelic dosage variables in the model of a specific V-gene. Assuming that the associations are caused by the residues' effects on V-gene expression, we refer to this posterior as the probability that a residue influences expression of a TCR V-gene.

In detail, our response vectors are the relative expression of each V-gene from a specific chain across the N=895 individuals. For a TCR chain with *T* paralog V-genes, we define a multiple response matrix **Y**~N×T~ with y~i,t~ being the standardized relative expression of TCR V-gene t∈{1,2,...,T} in individual i∈{1,2,...,N}. Our features are the imputed amino acid residues in each individual for each of the classical MHC genes (*HLA-A*, *HLA-B*, *HLA-C*, *HLA-DRB1*, *HLA-DQA1*, *HLA-DQB1*, *HLA-DPA1* and *HLA-DPB1*). The allelic dosage of a specific amino acid variant (a∈ {1,2,...,A~r~}) of a residue (*r*) of an MHC gene (*g*) in individual (*i*) is represented by a continuous variable x~i,(g,r,a)~ )∈\[0,2\]. For clarity, we also use below h∈{1,2,...,H} as the index for all possible combinations of (g,r,a). Our genotype matrix is therefore **X**~N×H~. We filtered out residues in which the maximal allele frequency was larger than 97.5% and dropped alleles with frequency lower than 0.5%. We define z~t,h~∈{0,1} to be an indicator of whether genotype x~h~ is included (has a coefficient β~t,h~\~ N(0,σ~β~^2^) or excluded (has a zero coefficient) from the model of y~t~. Together, the expression of gene t in individual i is modeled by

$$y_{i,t} = \sum\limits_{h}{x_{i,h}z_{t,h}\beta_{t,h}} + \varepsilon_{i}$$ where

$$\begin{array}{l}
{\left. z_{t,h} \right.\sim\text{Ber}(\pi_{h})} \\
{\left. \beta_{t,h} \right.\sim N(0,\sigma_{\beta}^{2})} \\
{\left. \varepsilon_{t,i} \right.\sim N(0,\sigma_{\varepsilon}^{2})} \\
\end{array}$$ independently, and
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Previous structural analysis of TCR-peptide-MHC complexes have found that a limited and consistent set of MHC residues interacts with the TCR and the docking orientation of the TCR is semi-conserved. This is reflected by the choice of the prior probability of z~t,h~=1 to be small and shared across V-genes (P(z~t,h~=1)= P~h~, for t∈{1,2,...,T}) and the modeling of α and β chain genes separately.

We consider that residue r of gene g influences the expression of TCR V-gene t, if at least one of the allelic dosage variables that represent it is in the model (i.e. its indicator variable z~t,(g,r,a)~ is equal to one). We denote this event F(Z,t,g,r): $$F(Z,t,g,r) = I(f(Z,t,g,r) > 0)$$ where

f

(

Z

,

t

,

g

,

r

)

=

(

∑

a

∈

{

1

,

2

,

...

A

(

g

,

r

)

}

z

t

,

(

g

,

r

,

a

)

)

\~

Bin

(

A

(

g

,

r

)

,

π

)

To avoid an *a priori* preference for residues with different numbers of possible alleles, we modified the prior beta distribution parameters of the indicator prior π~h~ in ([3](#FD3){ref-type="disp-formula"}) such that the *a priori* expectation and variance of F(Z,t,g,r) are equal for residues with different number of possible variants and match the prior in ([3](#FD3){ref-type="disp-formula"}) for a residue with two possible alleles.
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To find suitable values for the prior parameters, we assume that x~h~ is an allelic dosage variable of a residue r that has only two possible alleles and therefore is represented by a single dosage variable. We define π~h~\~ Beta(a,b) to be the prior of z~h~\~Ber(π~h~). Now let x~h\*~ be one of A dosage variables that represent a residue r\*, and π~h\*~\~ Beta(a\*,b\* ) be the prior of z~h\*~\~Ber(π~h\*~). We seek a\*,b\* such that the *a priori* expectation and variance of F over residue r\* are equal to the expectation and variance of F over residue r.

E

prior

θ

(

F

(

Z

,

t

,

g

,

r

)

)

=

E

prior

θ

(

F

(

Z

,

t

,

g

∗

,

r

∗

)

)

Var

prior

θ

(

F

(

Z

,

t

,

g

,

r

)

)

=

Var

prior

θ

(

F

(

Z

,

t

,

g

∗

,

r

∗

)

)

[Equation (8)](#FD8){ref-type="disp-formula"} is equal to

a

a

\+

b

=

E

(

1

\-

(

1

\-

π

h

∗

)

A

)

a

a

\+

b

=

1

\-

1

B

(

a

∗

,

b

∗

)

∫

0

1

(

1

\-

π

h

∗

)

A

π

h

∗

a

∗

\-

1

(

1

\-

π

h

∗

)

b

∗

\-

1

d

π

h

∗

b

a

\+

b

=

B

(

a

∗

,

b

∗

)

B

(

a

∗

,

b

∗

\+

A

)

Where B is the Beta function. In a similar manner [equation (9)](#FD10){ref-type="disp-formula"} is equal to: $$\frac{a + b(a + b + 1)}{(a + b)(a + b + 1)} = \frac{B(a^{\ast},b^{\ast} + 2A)}{B(a^{\ast},b^{\ast} + A)}$$

We then solved ([11](#FD12){ref-type="disp-formula"}) and ([12](#FD13){ref-type="disp-formula"}) numerically using R 'nleqslv' package to achieve (a\*,b\*) for various values of A.

In our analyses, the prior probability of any MHC residue to interact with a specific TCR V-gene was set at 0.1% and the prior probability of each position of the MHC to interact with any of the 44 TCR α V-genes was 4.3%, and 3.9% for any of the 40 TCR β chain V-genes.

To compute the posterior probability the posterior probabilities with which each MHC residue influences TCR V-gene expression that (i.e. E^θ\|X,Y^ (F(Z,t,g,r)) ) for all r) we sampled the space of possible models using an efficient Gibbs sampler^[@R65]^ where the likelihood is integrated over the coefficients (β)
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Altogether, we sampled 100,000 samples from 10 different starting points (excluding the first 2000 samples).

Structural analysis {#S15}
-------------------

A full list of TCR-pMHC structures and intermolecular interactions is curated by the international ImMunoGeneTics information system (IMGT^[@R66]^). We used all structures that were available in the protein databank (RCSB PDB^[@R67]^) on June 15, 2015. In order to compare the intermolecular interactions to the genetic analysis, the IMGT numbering was converted to the RCSB PDB numbering for all residues (RCSB PDB is indexed in the same manner as proteins in the UniProt database^[@R68]^). For the structure 4p4k, we converted the PDB numbering for the DP residues to the DQ and DR numbering using the IMGT labeling (for example, residue 72AG in the IMGT numbering equates to PDB residue 75 for DP structures, but 77 for all DP and DQ structures.) This allows for a more consistent comparison between the different alleles. The IMGT structural contact algorithm determined the structural contacts, which were defined as polar, non-polar, and hydrogen-bonds.

Pairwise Distance Analysis {#S16}
--------------------------

The distances between pairs of amino acid residues were calculated as the distance between the centroid of the amino acids using the PDB xyz coordinates for every atom in a given amino acid. This accounts for directionality of the side chains within the structure. For each MHC β chain residue, its minimum distance to any TCRα chain residue and its minimum distance to every peptide residue were calculated. For comparison, we also calculated the distance between the C~α~ of each residue using the PDB xyz coordinates of the C~α~'s ([Supplementary Fig. 28b](#SD1){ref-type="supplementary-material"}). The results using the two distance measurements are similar. A list of PDB files used can be found in [Supplementary Table 10](#SD1){ref-type="supplementary-material"}.
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![Illustration of our approach\
Expression of TCR V-genes in peripheral blood was estimated by mapping whole blood RNA-seq^[@R29]^ reads to V-genes while controlling for relevant individual level covariates and the total number of reads mapped to each TCR chain in that individual. Genotypes were measured genome-wide using Illumina HumanOmni1-Quad BeadChip^[@R29]^. MHC genotypes were imputed with SNP2HLA^[@R31]^. Associations between nucleotide or amino acid genotypes and V-gene expression were tested using Pearson correlations.](nihms798263f1){#F1}

![Expression of TCR Vα and Vβ genes is significantly associated with genetic variation in the MHC locus\
**(a--d)** Manhattan plots showing for each of 649,863 measured SNPs the most significant association across all V genes in each TCR α chain **(a)**, β chain **(b)**, γ chain **(c)** and δ chain. **(e--g)** Similar to (a--d) for immunoglobulin (Ig) λ chain **(e)**, κ chain **(f)** and heavy chain **(g). (h)** A Manhattan plot showing, for each of 13,732 tested genes, the most significant association between its expression and any of the 9,967 measured SNPs in the extended MHC locus. Excluded from the plot were all Ig and TCR V-genes, genes within 1Mb of the MHC locus, and one pseudogene with high sequence similarity to MHC (RNF5P1). Black horizontal lines correspond to a p-value of 5×10^−8^.](nihms798263f2){#F2}

![Expression of TCR Vα and Vβ genes is associated with amino acid variation in MHC proteins\
**(a)** Independent associations between Vα or Vβ expression and nucleotide or amino acid variation in the MHC locus (p\<0.05 with Bonferroni correction). SNPs are binned according to their genomic position (12Kb bins); points mark centerpoints of the classical MHC genes. For binning by equal numbers of SNPs see [Supplementary Fig. 10](#SD1){ref-type="supplementary-material"}. **(b)** and **(c)** show TCR Vα and TCR Vβ expression variation explained by amino acid variation in classical MHC genes and genetic variability in the MHC locus outside the transcribed regions of classical MHC genes. Values computed using GCTA^[@R33]^. Dots indicate that the total fraction of variation explained by the MHC gene components was significant at 5% FDR.](nihms798263f3){#F3}

![Bayesian inference of MHC amino acid residues that influence expression of TCR Vα genes\
**(a)** Estimated posterior probabilities that amino acid residues in *HLA-DRB1* (y-axis) influence expression of *each* TCR Vα gene (x-axis). Dots indicate positions with \>50% probability of influencing expression of a particular V gene. **(b)** Posterior probabilities that particular MHC amino acid residues influence expression of *any* TCR Vα-gene.](nihms798263f4){#F4}

![MHC residues that are functionally important for TCR recognition are also associated with TCR expression\
**(a)** Residue posterior probabilities of influencing expression of at least one TCR Vα-gene (yellow-red color scale) mapped onto a structure of *HLA-DRB1* (white) and *HLA-DRA1* (teal) (PDB ID: 2iam). **(b)** Similar to **a** but showing CDR1 (α blue, β green) and CDR2 (α magenta, β orange) loops of solved TCRs complexed with class II human MHC molecules. **(c)** Zoom-in on the consistent interaction between *HLA-DRB1* residue 77 (red) and TCR CDR loops in three different TCR-MHC complexes (top to bottom PDB IDs: 1j8h, 2iam and 3t0e). **(d)** Comparison of probabilities that *HLA-DRB1* residues influence expression of any TCR Vα-gene, and their frequency of physically contacting the TCR in ten DRB1/5 containing complexes. **(e)** Comparison of probabilities that MHC residues influence expression of at least one TCR Vα-gene (max over DRB1, DQB1 and DPB1), and their frequency of physically contacting the TCR and the peptide in 16 solved complexes (see also [Supplementary Fig. 15](#SD1){ref-type="supplementary-material"} and [Supplementary Table 4](#SD1){ref-type="supplementary-material"} lists the TCR Vα used in each structure).](nihms798263f5){#F5}
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